The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform
C Alberti - One of the best experts on this subject based on the ideXlab platform.
-
ophthalmic insert versus eye drops for Mydriasis in neonates a randomized clinical trial
Neonatology, 2019Co-Authors: Dominique Bremondgignac, E Jacqzaigrain, H Abdoul, A Beresniak, O Baud, Alejandra Daruich, C AlbertiAbstract:Background: Eye drop treatment routinely used to obtain Mydriasis prior to fundoscopy in neonates requires repeated instillations of mydriatic agents that can lead to systemic side effects. Objectives: The aim of this study was to compare the mydriatic efficacy and tolerance of administration of phenylephrine and tropicamide via the ophthalmic insert Mydriasert® versus standard eye drop treatment in neonates. Methods: In this prospective, single-blinded, noninferiority study, 80 hospitalized neonates (age < 18 months) requiring bilateral fundus examination were randomized to receive eye drops (repeated instillations of 2.5% phenylephrine and 0.5% tropicamide) or the insert. The primary outcome was Mydriasis suitable for fundoscopy 75 min after mydriatic agent introduction (T75). Results: Mydriasis was successfully achieved in both eyes at T75 in 97.5% (n = 39/40) of the insert group patients versus 90% (n = 36/40) receiving eye drops (between-group difference 7.5%, demonstrating noninferiority). Mydriasis remained stable in 60.0% of patients (n = 24/40) in the insert group versus 15% (n = 6/40) in the eye drop group (p < 0.0001). The insert group required fewer nursing interventions than the eye drop group (p = 0.0001). Mean blood pressure were significantly higher in the insert versus the eye drop group (p < 0.0001 and p = 0.0003, respectively); mean heart rate was not significantly different between the groups (p = 0.37). In the insert group, 2 patients reported an adverse event (bradycardia, n = 1, and gastroesophageal reflux, n = 1; both appeared to be related to neonate pathology). Conclusions: The degree of Mydriasis achieved with Mydriasert® was noninferior to that obtained with eye drops. The insert appears to be safe to use in neonates without a history of increased vagal tone or gastrointestinal reflux.
-
ophthalmic insert for pupillary Mydriasis in neonates
Acta Ophthalmologica, 2015Co-Authors: Dominique Bremondgignac, E Jacqzaigrain, H Abdoul, A Beresniak, O Baud, C AlbertiAbstract:Purpose To study efficacy and tolerance of ophthalmic insert Mydriasert® versus standard treatment phenylephrine and tropicamide eye drops for fundus examination in neonates. Methods Prospective, randomised, single-blinded non-inferiority study of 80 premature and full-term babies and infants treated for fundus examination. Mydriasis was obtained with two groups randomly assigned. The eye drop group received three instillations of 2.5% phenylephrine and 0.5% tropicamide and the insert group received Mydriasert® containing phenylephrine and tropicamide. the Mydriasis was evaluated 75 minutes after the introduction of the mydriatic agents. Results The Mydriasis was successfully achieved in both eyes in 97.5% of infants in the insert group and 90% in the eye drop group at 75 minutes after dispensation. The efficacy of the insert was non-inferior compared to the eye drops. To reach effective Mydriasis, the insert group required fewer nursing interventions for one patient comparing to the eye drop group. Good general and local tolerance was observed in the two groups. However two patients reported an adverse event as bradycardia and gastro-oesophageal reflux that could be related to neonate pathology. Conclusions Mydriasis obtained with the ophthalmic insert Mydriasert® was not inferior compared to standard eye drop treatment. Insert reduced the number of nursing interventions to obtain Mydriasis for a fundus examination.
Vikas Chopra - One of the best experts on this subject based on the ideXlab platform.
-
comparison of physiologic versus pharmacologic Mydriasis on anterior chamber angle measurements using spectral domain optical coherence tomography
Journal of Ophthalmology, 2015Co-Authors: Anna Dastiridou, Zhouyuan Zhang, Kenneth M Marion, Brian A Francis, Srinivas R Sadda, Vikas ChopraAbstract:Purpose. To compare the effects of physiologic versus pharmacologic pupil dilation on anterior chamber angle (ACA) measurements obtained with spectral domain optical coherence tomography (SD-OCT). Methods. Forty eyes from 20 healthy, phakic individuals with open angles underwent anterior segment OCT imaging under 3 pupillary states: (1) pupil constricted under standard room lighting, (2) physiologic Mydriasis in a darkened room, and (3) postpharmacologic Mydriasis. Inferior angle Schwalbe’s line-angle opening distance (SL-AOD) and SL-trabecular-iris-space area (SL-TISA) were computed for each eye and pupillary condition by masked, certified Reading Center graders using customized grading software. Results. SL-AOD and SL-TISA under pupillary constriction to room light were mm and mm2, respectively; decreased to mm and mm2 , respectively, under physiologic Mydriasis; and increased to mm and mm2 under pharmacologic Mydriasis compared to baseline. Conclusions. Using SD-OCT imaging, pharmacologic Mydriasis yielded the widest angle opening, whereas physiologic Mydriasis yielded the most angle narrowing in normal individuals with open iridocorneal angles. Accounting for the state of the pupil and standardizing the lighting condition would appear to be of importance for future studies of the angle.
Dominique Bremondgignac - One of the best experts on this subject based on the ideXlab platform.
-
ophthalmic insert versus eye drops for Mydriasis in neonates a randomized clinical trial
Neonatology, 2019Co-Authors: Dominique Bremondgignac, E Jacqzaigrain, H Abdoul, A Beresniak, O Baud, Alejandra Daruich, C AlbertiAbstract:Background: Eye drop treatment routinely used to obtain Mydriasis prior to fundoscopy in neonates requires repeated instillations of mydriatic agents that can lead to systemic side effects. Objectives: The aim of this study was to compare the mydriatic efficacy and tolerance of administration of phenylephrine and tropicamide via the ophthalmic insert Mydriasert® versus standard eye drop treatment in neonates. Methods: In this prospective, single-blinded, noninferiority study, 80 hospitalized neonates (age < 18 months) requiring bilateral fundus examination were randomized to receive eye drops (repeated instillations of 2.5% phenylephrine and 0.5% tropicamide) or the insert. The primary outcome was Mydriasis suitable for fundoscopy 75 min after mydriatic agent introduction (T75). Results: Mydriasis was successfully achieved in both eyes at T75 in 97.5% (n = 39/40) of the insert group patients versus 90% (n = 36/40) receiving eye drops (between-group difference 7.5%, demonstrating noninferiority). Mydriasis remained stable in 60.0% of patients (n = 24/40) in the insert group versus 15% (n = 6/40) in the eye drop group (p < 0.0001). The insert group required fewer nursing interventions than the eye drop group (p = 0.0001). Mean blood pressure were significantly higher in the insert versus the eye drop group (p < 0.0001 and p = 0.0003, respectively); mean heart rate was not significantly different between the groups (p = 0.37). In the insert group, 2 patients reported an adverse event (bradycardia, n = 1, and gastroesophageal reflux, n = 1; both appeared to be related to neonate pathology). Conclusions: The degree of Mydriasis achieved with Mydriasert® was noninferior to that obtained with eye drops. The insert appears to be safe to use in neonates without a history of increased vagal tone or gastrointestinal reflux.
-
ophthalmic insert for pupillary Mydriasis in neonates
Acta Ophthalmologica, 2015Co-Authors: Dominique Bremondgignac, E Jacqzaigrain, H Abdoul, A Beresniak, O Baud, C AlbertiAbstract:Purpose To study efficacy and tolerance of ophthalmic insert Mydriasert® versus standard treatment phenylephrine and tropicamide eye drops for fundus examination in neonates. Methods Prospective, randomised, single-blinded non-inferiority study of 80 premature and full-term babies and infants treated for fundus examination. Mydriasis was obtained with two groups randomly assigned. The eye drop group received three instillations of 2.5% phenylephrine and 0.5% tropicamide and the insert group received Mydriasert® containing phenylephrine and tropicamide. the Mydriasis was evaluated 75 minutes after the introduction of the mydriatic agents. Results The Mydriasis was successfully achieved in both eyes in 97.5% of infants in the insert group and 90% in the eye drop group at 75 minutes after dispensation. The efficacy of the insert was non-inferior compared to the eye drops. To reach effective Mydriasis, the insert group required fewer nursing interventions for one patient comparing to the eye drop group. Good general and local tolerance was observed in the two groups. However two patients reported an adverse event as bradycardia and gastro-oesophageal reflux that could be related to neonate pathology. Conclusions Mydriasis obtained with the ophthalmic insert Mydriasert® was not inferior compared to standard eye drop treatment. Insert reduced the number of nursing interventions to obtain Mydriasis for a fundus examination.
Hon Tym Wong - One of the best experts on this subject based on the ideXlab platform.
-
comparison of the influence of cataract and pupil size on retinal nerve fibre layer thickness measurements with time domain and spectral domain optical coherence tomography
Clinical and Experimental Ophthalmology, 2011Co-Authors: Clarissa Sm Cheng, Maricel Natividad, Arul Earnest, Vernon Yong, Hon Tym WongAbstract:Background: To investigate and compare the effect of cataract and pupil size on retinal nerve fibre layer (RNFL) thickness measurements using spectral-domain optical coherence tomography (Cirrus OCT) and time-domain OCT (Stratus OCT). Design: Prospective, hospital-based study. Participants: Twenty-five eyes from 25 normal subjects undergoing cataract surgery. Methods: Three retinal nerve fibre layer (RNFL) thickness measurements were taken before and after dilation, preoperatively and postoperatively, using Cirrus 200 × 200 Optic Disc Scan and Stratus Fast RNFL Scan. Main Outcome Measures: Linear regression, intraclass correlation coefficient (ICC) and coefficient of variation analysis. Results: Cataract removal caused significant increase in RNFL measurements in both modalities (Cirrus P 0.05). ICC showed excellent reproducibility with Cirrus OCT after Mydriasis, preoperatively (ICC = 0.78–0.90) and postoperatively (ICC = 0.90–0.97), but poor reproducibility before Mydriasis (P < 0.75). Stratus OCT achieved excellent reproducibility after cataract removal both before (ICC = 0.86–0.96) and after Mydriasis (ICC = 0.92–0.95), but poor reproducibility before cataract surgery (P < 0.75). Conclusions: Cataracts, not pupil size, cause significant underestimation of RNFL measurements in both Cirrus and Stratus OCT. The extent of influence exerted does not appear different between the two instruments. Reproducibility of each machine appears to be affected differently. Mydriasis is required to achieve excellent reproducibility with Cirrus OCT, and media clarity is required with Stratus OCT.
Tugba Atakan - One of the best experts on this subject based on the ideXlab platform.
-
unilateral transient Mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure
Clinical Ophthalmology, 2015Co-Authors: Sezen Akkaya, Hatice Kubra Kokcen, Tugba AtakanAbstract:We report a case of unilateral transient Mydriasis and ptosis after botulinum toxin injection applied by a medical doctor for a cosmetic procedure. A 36-year-old nurse was referred to our eye clinic with unilateral Mydriasis and ptosis in the right eye 3 days after botulinum toxin injection for a cosmetic procedure. Botulinum toxin was applied to her eye by a doctor at her hospital who was not an ophthalmologist. She was treated with topical apraclonidine 0.5% ophthalmic solution. Her ptosis decreased to 2 mm with apraclonidine and her visual axis improved. Mydriasis was present for 3 weeks and then disappeared. Mild ptosis continued for 3 months, then resolved completely. Patients seeking treatment with botulinum toxin A for cosmetic purposes should be warned about the possibility of ptosis and Mydriasis after injection. If these side effects are seen, the patient must be referred to an ophthalmologist for appropriate management.
